表紙:吸入式疼痛治療薬:進化する治療薬と新たな事業機会
市場調査レポート
商品コード
1235287

吸入式疼痛治療薬:進化する治療薬と新たな事業機会

Inhaled Pain Therapeutics: Evolving Therapeutics, Emerging Opportunities

出版日: | 発行: Greystone Research Associates | ページ情報: 英文 110 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
吸入式疼痛治療薬:進化する治療薬と新たな事業機会
出版日: 2023年01月31日
発行: Greystone Research Associates
ページ情報: 英文 110 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

先進国の平均寿命が延び、人口が高齢化するにつれて、慢性および急性の疼痛の発生率と関連する罹患率が増加し、患者とその家族にとってQOLの問題である疼痛管理がより重要視されるようになってきています。

当レポートでは、吸入式疼痛治療薬の市場を調査し、疼痛管理の概要、法規制環境、需要促進因子の分析、競合情勢、参入企業のプロファイルなどをまとめています。

目次

  • 吸入による疼痛管理
  • エグゼクティブサマリー
  • 疼痛管理の市場機会
  • 疼痛管理ガイドラインの進化
  • 疼痛管理の実践における地域的要因
  • 疼痛管理の需要促進要因
  • 競合情勢
  • 成長制限要因
  • 吸入技術、プラットフォーム、設計要因
  • 製剤
  • 製剤技術
  • 賦形剤と放出プロファイル
  • 経口吸入器の設計要因
  • ドライパウダー吸入器
  • 定量吸入器
  • ネブライザー
  • 鼻腔内吸入
  • 鼻腔内送達の薬物動態
  • 鼻腔内器具の特徴
  • パフォーマンス要因
  • バイオアベイラビリティ
  • 用量再現性
  • 活性化合物の安定性
  • 吸入薬の主要な短期疼痛市場
  • 癌突出痛 (cBTP)
  • 片頭痛と群発頭痛
  • 中度から重度の痛み
  • 吸入疼痛管理製品
  • FDA承認薬
  • AstraZeneca
  • GlaxoSmithKline
  • Valeant
  • Mylan/Roxane/Apotex
  • Ketorolac
  • 開発段階の医薬品
  • Butorphanol
  • Fentanyl
  • Dihydroergotamine
  • Ketamine
  • Morphine
  • Perchlorperazine
  • Triptans
  • 市場要因
  • 使いやすさ・患者の好み
  • 規制上の問題
  • 患者コンプライアンス
  • CMO/CSOの役割
  • 企業プロファイル
目次

‘Inhaled Pain Management: Evolving Therapeutics, Emerging Opportunities’ is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for inhaled pain management drug therapeutics. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

User-friendly Administration for a Diverse and Growing Therapeutic Need

As life expectancy in the developed world increases and populations age, the incidence and associated morbidity of chronic and acute pain is increasing and placing a higher level of emphasis on pain management as a quality-of-life issue for patients and their families. Responding to this trend, drug developers are increasingly turning to inhalable formulations of pain management drugs. Because it has the potential to improve drug therapy compliance, inhaled pain drug delivery addresses a key healthcare issue - one that is particularly problematic in aging populations and developing economies. Several of these development programs involve international partnerships designed to take advantage of perceived opportunities in regional markets.

What You Will Learn:

  • Analyzes and evaluates inhaled pain management drugs currently in development and assesses the market potential for existing and probable future products.
  • Examines inhalation device technology for commercial and development-stage devices, and evaluates product technology issues and evolving market factors for inhaled pain management therapeutics.
  • Provides detailed assessments of market segments, market potential, and growth prospects.
  • Forecasts the impact of new and emerging inhaled pain management drug therapeutics on healthcare markets and prescribing decisions.
  • Profiles Inhaled pain management drug product market participants, their technology, product development activity, and business strategies.
  • Evaluates the impact of economic, technology, and regulatory factors on market sector companies and their alliance partners.

Table of Contents

  • Inhaled Pain Management
  • Executive Summary
  • The Pain Management Market Opportunity
  • Evolution in Pain Management Guidelines
  • Regional Factors in Pain Management Practice
  • Pain Management Demand Drivers
  • Competitive Landscape
  • Factors Limiting Growth
  • Inhalation Technology, Platforms and Design Factors
  • Drug Formulations
  • Formulation Technologies
  • Excipients and Release Profiles
  • Oral Inhalation Device Design Factors
  • Dry Powder Inhalers
  • Metered Dose Inhalers
  • Nebulizers
  • Intranasal Inhalation
  • Intranasal Delivery Pharmacokinetics
  • Intranasal Device Characteristics
  • Performance Factors
  • Bioavailability
  • Dose Reproducibility
  • Active Compound Stability
  • Key Near-Term Pain Markets for Inhaled Drugs
  • Breakthrough Cancer Pain
  • Migraine and Cluster Headaches
  • Moderate to Severe Pain
  • 1Inhaled Pain Management Products
  • FDA-Approved Drugs
  • AstraZeneca
  • GlaxoSmithKline
  • Valeant
  • Mylan/Roxane/Apotex
  • Ketorolac
  • Development-Stage Drugs
  • Butorphanol
  • Fentanyl
  • Dihydroergotamine
  • Ketamine
  • Morphine
  • Perchlorperazine
  • Triptans
  • Market Factors
  • Usability and Patient Preferences
  • Regulatory Issues
  • Patient Compliance
  • The Role of CMOs/CSOs
  • Company Profiles